Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism and Excretion of [14C]ASP8273 in EGFR-mutated Solid Tumors
NCT02674555Phase 1Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of naquotinib in solid tumor, sponsored by Astellas Pharma. Primary endpoints: Radioactivity in whole blood: AUCinf up to 14 days, Radioactivity in whole blood: AUClast up to 14 days and 26 more. Planned start Nov 2016; status: withdrawn.
02
Drugs
naquotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02674555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674555.